The Chromosomal Microarray Analysis (CMA) Testing segmentation by application delineates four primary demand drivers: prenatal diagnosis, postnatal diagnosis, oncology, and research use. Prenatal diagnosis, accounting for roughly 45 % of total revenue, dominates because it enables early detection of aneuploidies and sub‑microscopic deletions, prompting higher reimbursement rates and widespread adoption in obstetric care. Postnatal diagnosis contributes about 35 % and is driven by the need to resolve developmental delay, intellectual disability, and congenital anomalies, where CMA supersedes conventional karyotyping in diagnostic yield. Oncology, representing ~15 % of the market, leverages CMA to identify copy‑number variations that influence tumor classification and targeted therapy selection, though its penetration remains limited by competing next‑generation sequencing platforms. Research applications, at ~5 %, involve gene‑function studies and population‑level screening, supporting incremental growth but remaining a niche segment. Collectively, these application categories shape the overall market size by dictating pricing structures, reimbursement pathways, and geographic adoption patterns.